Nigerian start-up 54gene seeks to be the first private sector enterprise bent on applying Africa’s rich genetic heritage to solve the world’s most intractable diseases – ethically, without boundaries, for all.

Adjuvant Capital believes its fund will ultimately lead to greater access to medical advances in low-income countries while making a healthy return for its high-profile investors.